S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Neusoft Secures Spot in 2026 IDC China FinTech Power Force 50

Shenyang-based technology firm Neusoft Corporation has earned a position in the 2026 IDC China FinTech Power Force 50, a ranking that identifies providers with proven business maturity and extensive service capabilities. The recognition highlights the company's role in delivering mission-critical solutions to the evolving financial sector.

The IDC selection process evaluates candidates based on four pillars: market adoption, end-to-end service delivery, regulatory compliance, and overall industry impact. Neusoft’s inclusion underscores its technical competitiveness in core banking systems, intelligent risk control, and regulatory compliance software. By leveraging its self-developed platforms, the company serves as a critical infrastructure partner for financial institutions navigating complex operational requirements.

Neusoft’s market position is built on three decades of experience managing data within highly regulated environments. The firm utilizes a full-stack approach to convert distributed enterprise data into measurable business value, alongside a framework for responsible artificial intelligence deployment. As China’s fintech sector shifts toward more advanced development, Neusoft intends to utilize its accumulated expertise to capture emerging growth opportunities, focusing on high-stakes financial operations that require both technical robustness and deep industry insight.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!